Table of Contents
- Overview of the Insulin Glargine trials
- Trials in type 2 diabetes
- Trials in type 1 diabetes
- What Insulin Glargine is being compared with
- Main endpoints and what they mean
- Who the studies are for
- Study design and phases
Overview of the Insulin Glargine trials
The source data shows several Phase 3 clinical trials that include Insulin Glargine as a study treatment, a comparison treatment, or background insulin therapy.[1] These studies are focused mainly on diabetes, especially type 1 diabetes and type 2 diabetes.[1]
Most trials are interventional, which means people receive a treatment and researchers compare outcomes between groups.[1] The main outcome in many studies is HbA1c, a test that shows average blood sugar over time.[1]
Trials in type 2 diabetes
Several studies focus on adults with type 2 diabetes, including people with overweight, obesity, or higher cardiovascular risk.[1] One study compared once-weekly insulin icodec with daily basal insulins in adults with type 2 diabetes, with HbA1c change after 52 weeks as the main endpoint.[1]
Another study compared oral orforglipron with Insulin Glargine in people with type 2 diabetes and obesity or overweight at increased cardiovascular risk, and it measured time to the first major adverse cardiovascular event, also called MACE-4.[1] MACE-4 includes heart attack, stroke, hospitalization for unstable angina, or cardiovascular death.[1]
The SUSTAIN OPTIMIZE study looked at semaglutide plus a lower dose of Insulin Glargine compared with a higher dose of Insulin Glargine alone in people with type 2 diabetes and overweight.[1] Its main goal was to compare HbA1c change after 40 weeks.[1]
REIMAGINE 3 studied people with type 2 diabetes treated with once-daily basal insulin, including Insulin Glargine, with or without metformin.[1] This study measured whether CagriSema lowered blood sugar and body weight better than placebo, using change in HbA1c as the main endpoint.[1]
Other type 2 diabetes studies used Insulin Glargine as part of treatment selection or comparison when testing new approaches, such as switching from daily basal insulin to weekly insulin icodec, or studying IcoSema against daily Insulin Glargine.[1] These trials mainly focused on glycaemic control, which means how well blood sugar is managed.[1]
Trials in type 1 diabetes
One Phase 3 study in adults with type 1 diabetes compared once-weekly insulin icodec with once-daily Insulin Glargine U100, and both groups also used insulin aspart.[1] The main endpoint was the change in HbA1c from baseline to week 26.[1]
This study was designed to show that the weekly insulin was not meaningfully worse than daily Insulin Glargine by more than a set limit, which is called non-inferiority.[1] In simple terms, the trial asked whether the new treatment could work about as well as the standard one.[1]
What Insulin Glargine is being compared with
In the trial data, Insulin Glargine appears in several roles: as the main comparison treatment, as a background insulin, or as part of a treatment strategy being adjusted.[1] It is compared with weekly insulin icodec, IcoSema, oral orforglipron, semaglutide, and placebo in different studies.[1]
Some studies compare Insulin Glargine with other basal insulins or insulin products such as insulin degludec, insulin detemir, Toujeo, Tresiba, and Levemir, depending on the trial question.[1] The purpose is to see whether a new treatment is as effective, more effective, or easier to use.[1]
Main endpoints and what they mean
The most common endpoint is change in HbA1c, which shows whether blood sugar control improved over time.[1] Many trials measure HbA1c at 26, 40, or 52 weeks.[1]
Some studies also look at cardiovascular outcomes, such as major heart and blood vessel events.[1] The orforglipron study used time to first MACE-4 event as the main endpoint.[1]
Other endpoints are more practical and study how the trial itself works, such as time to enrolment, study completion, diversity of participants, treatment adherence, safety reporting, and data quality.[1] These are important because they show whether a trial design can work well in real-life settings.[1]
Who the studies are for
The trials mainly include adults with type 1 diabetes or type 2 diabetes.[1] Some studies also focus on people with overweight, obesity, chronic kidney disease, or increased cardiovascular risk.[1]
In the biomarker study, people with type 2 diabetes were grouped by whether they had more insulin resistance or more insulin secretion deficit.[1] This means the researchers were trying to see whether different patient types respond differently to treatment.[1]
The RADIAL study included people with type 2 diabetes mellitus treated with Toujeo and tested a decentralised trial approach, which means more of the study could happen outside a traditional hospital setting.[1] That study looked at recruitment, retention, diversity, satisfaction, adherence, and data quality.[1]
Study design and phases
All listed studies are Phase 3 and interventional in design.[1] Phase 3 studies are larger trials that compare treatments in real patient groups and help confirm how well a treatment works.[1]
Enrollment numbers range from smaller studies with 80 participants to larger studies with more than 2,000 participants.[1] This wide range shows that some trials are focused on detailed questions in smaller groups, while others are built to compare outcomes in much larger populations.[1]
